Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 3/20 | 0.61 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.61 |
| ▸ | ULK2 | Q8IYT8 | 3/20 | 0.61 |
| ▸ | SYK | P43405 | 3/20 | 0.58 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | TBK1 | Q9UHD2 | 7/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.57 |
| ▸ | BMPR2 | Q13873 | 2/20 | 0.57 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.57 |
| ▸ | TYK2 | P29597 | 2/20 | 0.57 |
| ▸ | STK16 | O75716 | 1/20 | 0.57 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.57 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.57 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.57 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.57 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.57 |
| ▸ | MARK3 | P27448 | 3/20 | 0.54 |
| ▸ | MARK4 | Q96L34 | 3/20 | 0.54 |
| ▸ | AURKA | O14965 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL914293 | 0.91 | ULK1 (0.67) | ULK1PDK1ULK2SYKPDPK1 | |
| SCHEMBL913729 | 0.89 | ULK1 (0.59) | ULK1PDK1ULK2SYKPDPK1 | |
| SCHEMBL912996 | 0.89 | ULK1 (0.59) | ULK1PDK1ULK2SYKPDPK1 | |
| SCHEMBL913548 | 0.88 | STAT6 (0.67) | ULK1PDK1ULK2SYKTBK1 | |
| SCHEMBL913883 | 0.88 | SYK (0.59) | ULK1PDK1ULK2SYKPDPK1 | |
| SCHEMBL913730 | 0.88 | ULK1 (0.59) | ULK1PDK1ULK2SYKPDPK1 | |
| SCHEMBL914035 | 0.87 | STAT6 (0.68) | ULK1PDK1ULK2SYKTBK1 | |
| SCHEMBL12904961 | 0.87 | ULK1 (0.56) | ULK1PDK1ULK2SYKPDPK1 | |
| SCHEMBL3722244 | 0.87 | ULK1 (0.61) | ULK1PDK1ULK2PDPK1CDK2 | |
| SCHEMBL913657 | 0.86 | STAT6 (0.65) | ULK1PDK1ULK2SYKTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | claimed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | claimed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2010129802-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129802-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137673-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | ULK1 449/4885PDK1 524/4885ULK2 221/4885 |
| US-20110005947-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | ULK1 449/4885PDK1 524/4885ULK2 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.